Liise-anne Pirofski

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6017140/publications.pdf

Version: 2024-02-01

46 papers	2,705 citations	236925 25 h-index	315739 38 g-index
56 all docs	56 docs citations	56 times ranked	5790 citing authors

#	Article	IF	Citations
1	The convalescent sera option for containing COVID-19. Journal of Clinical Investigation, 2020, 130, 1545-1548.	8.2	775
2	Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. Journal of Proteomics, 2014, 106, 46-60.	2.4	203
3	A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition. Cell Host and Microbe, 2020, 28, 486-496.e6.	11.0	178
4	The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis. Mayo Clinic Proceedings, 2021, 96, 1262-1275.	3.0	129
5	Microbiology: Ditch the term pathogen. Nature, 2014, 516, 165-166.	27.8	99
6	A Randomized Trial of Convalescent Plasma for COVID-19â€”Potentially Hopeful Signals. JAMA - Journal of the American Medical Association, 2020, 324, 455.	7.4	90
7	What Is a Host? Incorporating the Microbiota into the Damage-Response Framework. Infection and Immunity, 2015, 83, 2-7.	2.2	89
8	The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases. Advances in Experimental Medicine and Biology, 2008, 635, 135-146.	1.6	81
9	A Human IgM Monoclonal Antibody Prolongs Survival of Mice with Lethal Cryptococcosis. Journal of Infectious Diseases, 1998, 178, 1213-1216.	4.0	78
10	A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine. Science Translational Medicine, 2017, 9, .	12.4	73
11	Use of convalescent plasma in<scp>COVID</scp>â€19 patients with immunosuppression. Transfusion, 2021, 61, 2503-2511.	1.6	70
12	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	5.1	63
13	The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19. MBio, 2021, 12, .	4.1	62
14	Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework. MBio, 2020, 11, .	4.1	54
15	Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis. ACS Omega, 2021, 6, 85-102.	3.5	54
16	A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. Cell Chemical Biology, 2016, 23, 1407-1416.	5.2	51
17	Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in Medicine, 2021, 8, 684151.	2.6	50
18	SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. Journal of Clinical Investigation, 2021, 131, .	8.2	47

#	Article	IF	Citations
19	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. Nature Communications, 2021, 12, 6853.	12.8	41
20	Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19. JAMA Network Open, 2022, 5, e2147331.	5.9	38
21	Treatment of Severe COVID-19 with Convalescent Plasma in Bronx, NYC. JCI Insight, 2021, 6, .	5.0	36
22	COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses, 2021, 13, 1594.	3.3	31
23	The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases. PLoS Pathogens, 2015, 11, e1004717.	4.7	30
24	Developing Interactive Antimicrobial Stewardship and Infection Prevention Curricula for Diverse Learners: A Tailored Approach. Open Forum Infectious Diseases, 2017, 4, ofx117.	0.9	27
25	Benefits and Costs of Animal Virulence for Microbes. MBio, 2019, 10, .	4.1	27
26	Early Infectious Disease Consultation Is Associated With Lower Mortality in Patients With Severe Sepsis or Septic Shock Who Complete the 3-Hour Sepsis Treatment Bundle. Open Forum Infectious Diseases, 2019, 6, ofz408.	0.9	25
27	Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody. MBio, 2016, 7, e02260-15.	4.1	19
28	The Assessment of Convalescent Plasma Efficacy against COVID-19. Med, 2020, 1, 66-77.	4.4	17
29	Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans. Infection and Immunity, 2020, 88, .	2.2	16
30	An Ahemolytic Pneumolysin ofStreptococcus PneumoniaeManipulates Human Innate and CD4⁺T-Cell Responses and Reduces Resistance to Colonization in Mice in a Serotype-Independent Manner. Journal of Infectious Diseases, 2014, 210, 1658-1669.	4.0	14
31	Is Burnout Infectious? Understanding Drivers of Burnout and Job Satisfaction Among Academic Infectious Diseases Physicians. Open Forum Infectious Diseases, 2019, 6, ofz092.	0.9	14
32	Of Mice and Men, Revisited: New Insights into an Ancient Molecule from Studies of Complement Activation by Cryptococcus neoformans. Infection and Immunity, 2006, 74, 3079-3084.	2.2	12
33	Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. New England Journal of Medicine, 2021, 384, 189-189.	27.0	12
34	Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts. MSphere, 2021, 6, .	2.9	11
35	Extracellular Vesicles from Different Pneumococcal Serotypes Are Internalized by Macrophages and Induce Host Immune Responses. Pathogens, 2021, 10, 1530.	2.8	7
36	WHO covid-19 drugs guideline: reconsider using convalescent plasma. BMJ, The, 2022, 376, o295.	6.0	6

#	Article	IF	Citations
37	Life as an Infectious Diseases Physician Scientist: Science is Humanityâ€™s Lifeline. Journal of Infectious Diseases, 2017, 216, S611-S612.	4.0	4
38	Antibody Immunity and Natural Resistance to Cryptococcosis. Current Tropical Medicine Reports, 2019, 6, 50-54.	3.7	3
39	Cryptococcus neoformans-specific and non-Cryptococcous neoformans-specific antibody profiles in organ transplant recipients with and without cryptococcosis. Open Forum Infectious Diseases, 0, , .	0.9	2
40	Acquired Antibody-Mediated Immunity to Fungi. , 0, , 487-503.		1
41	Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma. , 0, , 537-546.		1
42	Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination. Vaccine Journal, 2016, 23, 524-529.	3.1	0
43	Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseasesâ€“Critical Care Medicine Service in Critical Care Units. Open Forum Infectious Diseases, 2021, 8, ofab182.	0.9	0
44	Acquired Humoral Immunity to Cryptococcus neoformans. , 0, , 397-408.		0
45	Report from the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Joint Conference 2008: Washington, DC, USA, October 25-28, 2008. Journal of Invasive Fungal Infections, 2009, 2, 151-154.	0.0	0
46	mBio Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions. MBio, 2022, , e0052722.	4.1	0